Skip to search formSkip to main contentSkip to account menu

factor V Leiden

Known as: leiden factor v, factor V G1691A, FV Leiden 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Both tamoxifen and the factor V Leiden (FVL) mutations are wellestablished risk factors for thromboembolic events (TE). Tamoxifen… 
Review
2009
Review
2009
The aim of this review was to compile published data on factor V 1691 G-A alteration in a healthy Turkish population and also to… 
2008
2008
Summary Venous thromboembolism (VTE) is three-fold higher among FV Leiden (FVL) carriers receiving oral contraceptives (OCPs… 
2007
2007
The number of women in private and public organizations is increasing, but they are not reaching top management levels. Women are… 
2006
2006
BACKGROUND Factor V Leiden (FVL) is a common genetic risk factor for vascular thrombosis in humans. Fabry disease, an X-linked… 
2005
2005
Summary About 60% of patients diagnosed with acute thrombotic thrombocytopenic purpura (TTP) display a severe ADAMTS13 deficiency… 
2005
2005
s of all RAND Health publications and full text of many research documents can be found on the RAND Health web site at www.rand… 
2004
2004
Objective: To investigate the association of two common prothrombotic mutations, factor V G1691A (FV G1691A) and prothrombin… 
Highly Cited
2003
Highly Cited
2003
Inherited prothrombotic risk factors predispose patients to thromboembolic events. In kidney transplant recipients, thrombophilia… 
Highly Cited
2003
Highly Cited
2003
BACKGROUND AND OBJECTIVES A complex haplotype of factor V gene (FV HR2) has been recently reported. FVHR2 possesses decreased co…